Anwaar Saeed

Clinical trials

• Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

  Principal investigator · Recruiting · Phase 1, Phase 2

  National Cancer Institute (NCI)

  2025–2027
• 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

  Principal investigator · Recruiting · Phase 1

  Anwaar Saeed

  2025–2028
• Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

  Principal investigator · Recruiting · Phase 2

  Anwaar Saeed

  2024–2027
• Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

  Principal investigator · Terminated · Phase 2

  Anwaar Saeed

  2024–2025